{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-114839","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.356960+00:00","generated_at":"2026-05-30T13:52:21.971695+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio receives FDA clearance to evaluate ADI-001 in IIM and Stiff Person Syndrome","bullets":["FDA cleared IND amendment for ADI-001 to treat idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).","Patient enrollment for IIM/SPS cohort expected to start Q1 2025; Phase 1 now covers six autoimmune diseases.","Phase 1 program has four arms: LN/SLE, SSc, AAV, and combined IIM/SPS cohort.","Initial clinical data from Phase 1 in autoimmune diseases expected first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-114839","json":"https://secwatch.observer/filing/0000950170-24-114839.json","markdown":"https://secwatch.observer/filing/0000950170-24-114839.md","text":"https://secwatch.observer/filing/0000950170-24-114839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024114839/0000950170-24-114839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024114839/acet-20241016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:52:21.971695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}